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Management of Impotence After Treatment of Carcinoma
of the Prostate

Dinesh J. Telang, MD,* and Riad N. Farah, MD*

Impotence commonly occurs as a resuh of treatment of carcinoma ofthe prostate. We review the
etiology, evaluation, and treatment options availahle for these patients as weU as our experience with
fifty prostate cancer patients who underwent placement of penile prostheses. Several excellent
alternatives are availahle for patients with impotence resulting from treatment of carcinoma ofthe
prostate. (Henry Ford Ho.sp MedJ 1992:40:111-3)

I

mpotence from treatment of carcinoma of the prostate occurs
with all known modalities of treatment, including radical
prostatectomy, extemal beam radiation therapy, and hormonal
therapy.
The incidence of postoperative impotence was 91% to 100%
(1) until Walsh et al (2) first described the nerve-sparing anatomic approach to radical retropubic prostatectomy in 1983.
Walsh et afs description of the anatomy of the dorsal vein complex and the neurovascular bundles (which innervate the cavernosal bodies responsible for erection) revived interest in performing radical surgery for localized cancer of the prostate.
These techniques brought morbidity, in terms of impotence, incontinence, and blood loss, to an acceptable level. Of 61 potent
patients undergoing nerve-sparing prostatectomy by a single
staff urologist at Henry Ford Hospital between January 1986 to
June 1990,57% regained potency within one year of their operation (3). Not all patients, however, are candidates for nerve-sparing prostatectomy because of the stage or the location ofthe tumor within the prostate. Regaining erectile function is also
highly dependent on other factors, most importantiy age (4).
Extemal beam radiation therapy causes local fibrosis and
sclerosis of tissues which may result in erectile dysfunction of
vascular and/or neurologic origin. Impotence ranged from 40%
to 60% in one reported series (5).
Hormonal therapy, usually reserved for locally advanced or
metastatic adenocarcinoma of the prostate, consists of exogenously administered luteinizing hormone-releasing hormone
analogues (leuprolide, goserelin acetate), estrogens (diethylstilbestrol), or surgical castration. While its mechanisms are not
completely understood, circulating testosterone is responsible
for libido and plays a role in maintaining erectile function.

guided by the patient and his partner's preference. A detailed
history and physical and neurological examinations are necessary. Other testing, such as noctumal penile tumescence testing
and psychometric examinations, may be requested in some instances. Intracavemosal injection of vasoactive substances such
as papaverine or prostaglandin E can be used in evaluation as
well as in treatment.

Treatment
Treatment options for impotence (from least to most invasive) include oral pharmacologic therapy, hormonal therapy,
vacuum suction and penile constriction devices, intracavemosal
injection therapy, penile revascularization and venous ligation
procedures, and an anay of available penile prostheses. Hormonal therapy (testosterone injection) is contraindicated in patients
with a history of prostate cancer because of the androgen-dependent nature of the disease. Revascularization procedures are
generally reserved for younger patients with isolated arterial inflow disease (from trauma, for example). Our discussion will be
limited to those modalities of clinical use in the prostate cancer
patients.
Oral pharmacologic therapy
Yohimbine HCL is an indolic alkaloid obtained from the
yohimbine tree. Yohimbine blocks presynaptic alpha-2 adrenergic receptors; the net effect on the peripheral autonomic nervous
system is to decrease sympathetic outflow and increase parasympathetic activity, tt may act to elevate mood and anxiety and
has been used in the past as an aphrodisiac. Since erection is
cholinergically mediated through the parasympathetic nervous
system, yohimbine may potentiate penile inflow, decrease out-

Evaluation
The evaluation of impotence after treatment of prostate cancer is somewhat simplified since the etiology of the impotence is
clear and, perhaps more importantly, method of treatment is

Henry Ford Hosp Med J—Vol 40. Nos I & 2, 1992

Submitted for publication; August 27, 1992.
Accepted for publication; September 2, 1992.
"'Department of Urology, Henry Ford Hospital.
Address correspondence to Dr. Farah, Department of Urology, Henry Ford Hospital
2799 W Grand Blvd, Detroit, Ml 48202.

Management of Impotence from Prostate Cancer—Telang & Farah

111

flow, or both (6). A recent published report noted no improvement in performance when comparing yohimbine to placebo
(7).

Vacuum suction and penile constriction devices
Vacuum suction and penile constriction devices involve
placement of a cylindrical apparatus over the penis, which
pumps out air and creates vacuum to engorge the penis; a constricting band is then placed over the base of the phallus to maintain the erection. Advantages include low cost, low morbidity,
and high satisfaction rates in patients with excellent manual
dexterity who are highly motivated and have a supportive partner (8). There have been no reports of serious complications, although some patients complain of numbness while the constricting band is in ptace. These devices have been utilized successfully in some patients who have had penile prostheses explanted and can be used in combination with intracavemosal injection therapy (9).
Intracavemosal injection therapy
Use of intracavemosal injection of vasoactive agents is a relatively recent development in the treatment of impotence. Early
reports used papaverine with or without phentotamine; more recentiy prostaglandin E, alone or in various combinations with
papaverine and phentotamine, has found favor. Advantages of
intracavemosal injection include a physiologic erection that can
be produced "on demand," the temporal nature of the treatment,
and ease of administration. Insulin-dependent diabetic patients
seem to be especially well suited to this type of therapy. Risk of
infection is exceedingly low when used with proper sterilization
techniques.
As with vacuum constriction devices, injection therapy requires a high level of manual dexterity as welt as a highly motivated patient, tt does not preclude use of other treatment options
should it not be an acceptable solution for a couple's sexual dysfunction. Disadvantages include pain with injection and the
need to stock necessary syringes, needles, and medication.
Complications include corporeal fibrosis (more common with
papaverine) and priapism. One-year dropout rates from pharmacologic erection programs have been as high as 40% to 50%
(10).
Penile prostheses
Modem silicone penile prostheses were introduced in the mid
1960s. Several options are available. Semirigid prostheses are
solid siticone with a centrat silver or stainless-steel wire to give
rigidity. Mechanical failures are uncommon, and patient satisfaction is high. The prosthesis is simply bent into position as desired, requiring minimal manual dexterity. While these prostheses are simple to use, some patients complain of difficulty concealing these devices when not in use.
The first inflatable penile prosthesis was developed in 1973;
plagued with problems early on, subsequent design improvements have made the inflatable models reliable with 97% functioning at three years in one study (11). The inflatable models
closely mimic the appearance of a normal physiologic erection,
are self-contained, and require no extemal paraphemalia. Pa-
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tient satisfaction ranges from 83% to near 90%, with partner satisfaction somewhat lower (12-14). Complications range from
the need for simple revisions for mechanical failure to infection
and erosion to gangrene of the penis. These complications are
more likely to occur in poorly controlled diabetics; patients with
neurogenic bladders on clean intermittent catheterization; patients with urinary diversions, cystostomy tubes, or colostomy;
and paraplegics (15).
We have extensive experience with penile prostheses at
Henry Ford Hospital, with over 870 devices placed by a single
staff urologist. We recently reviewed the medical records of 50
patients with a history of carcinoma of the prostate who underwent placement of a penile prosthesis. Patients ranged in age
from 50 to 78 years (mean 65 years). Thirty-five patients elected
inflatable prostheses; the remainder chose semirigid implants.
Overall mean follow-up is 4.3 years (7.4 years for semirigid
prostheses and 3.0 years for inflatable devices). The shorter follow-up for inflatable prostheses is attributed to improvements in
design in these prostheses in recent years.
Five men underwent removal or revision of the prosthesis.
One patient had his semirigid prosthesis removed because of
problems with concealment; he refused revision to an inflatable
model. Two patients had simple revisions (one from a semirigid
to an inflatable prosthesis for erosion and the other for a pump
malfunction); both of these patients cunently have functioning
implants. The other two men had two or more unsuccessful revisions or replacements of their inflatable prosthesis ultimately resulting in removal of the device because of erosion or infection.
These two patients have not been interested in further evaluation
or treatment.
The long-term complication rate in our series is 8%, half of
which have been managed successfully. Risk factors for complications included diabetes in one patient and history of urinary
tract infection in two patients. Thirteen of 15 patients with
semirigid implants have had an uncomplicated postoperative
course; 32 of 35 patients with inflatable implants have had no
mechanical or technical problems with the device. The 90%
complication-free rate and the 94% functional prosthesis rate
are excellent in a cancer patient population. These rates are comparable to a previously reported series (10). Patient and partner
satisfaction with penile prostheses at our institution is cunently
being studied. In a series from the Mayo Clinic (12), patients
who required more than one procedure for implantation of the
prosthesis or who experienced pain or were dissatisfied with the
cosmetic appearance of the device were least likely to be satisfied with the prosthesis.

Cost
The relative cost of intracavemosal injection versus semirigid and inflatable penile prostheses has been studied. Buch et
al (16) compared the calculated projected cost of intracavernosal injection over afive-yearperiod ($3,450) to the cost of a
semirigid ($3,150) or inflatable penile prosthesis ($9,000) and
concluded that prostheses were more cost-effective than intracavemosal injection for young patients. However, this study did
not calculate the cost of complications, revisions, or life expec-

Management of Impotence from Prostate Cancer—Telang & Farah

tancy of the patient or the prosthetic device. Vacuum suction
and penile constriction devices cost approximately $300, Prostaglandin El ranges from $3 to $10 per injection depending on
the dose required to obtain a satisfactory erection. Interestingly,
insurance companies are highly variable with respect to coverage for evaluation and treatment of organic impotence

Conclusion
Impotence secondary to carcinoma of the prostate is becoming increasingly more common as new methods of early detection have been developed (specifically prostate-specific antigen
and transrectal sonography) and are now widely available. Several excellent treatment altematives are available to prostate
cancer patients with sexual dysfunction. With careful evaluation
an acceptable and effective method of treatment is available to
almost all of these patients.
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